PBAC's latest decision on Efalizumab: Recommended with restriction (2008). Considered for Extension of initial treatment phase from 12 to 24 weeks for chronic plaque psoriasis in patients who achieve a PASI over 50 and less than 75 at 12 weeks.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
3
first 2005
Submissions
3
2005 → 2008
Eligible population
Patients with severe refractory chronic plaque psoriasis who achieve a PASI over 50 and less than 75 at 12 weeks of efalizumab treatment.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
PASI ≥ 75% response
Key trials
24011, 2390, 2391, 2059, 2058, 2243, 2600
Comparator
efalizumab using a 12-week initial treatment period
Economic model
CUA
ICER basis
Range aggregates 3 submissions (2005–2008) — not a single base case.
Submission history
Jul 2005: Not recommended · Authority Required — ICER $75k/QALY
Nov 2005: Recommended with restriction · Authority Required — ICER $75k/QALY
Nov 2008: Recommended with restriction · Restricted — ICER $45k/QALY